|
TUESDAY, DECEMBER 7, 2021 |
| All times are CENTRAL Time |
|
|
| |
|
|
|
8:00 am - 8:15 am CT |
WELCOME AND OPENING REMARKS |
|
|
|
Virginia G. Kaklamani, MD
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
|
|
| 8:15 am - 10:45 am CT |
GENERAL SESSION 1
|
|
| 8:15 am |
GS1-01 KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC)
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Hee Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Baron-Hay S, Boileau J-F, Zhu Y, Pan W, Tryfonidis K, Vassiliki Karantza V, O’Shaughnessy J. Barts Cancer Institute, Queen Mary University London, London, United Kingdom; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; National Cancer Center Singapore, Duke-NUS Medical School, Singapore, Singapore; Yale School of Medicine, Yale Cancer Center, New Haven, CT; Cedars-Sinai Medical Center, Los Angeles, CA; Kliniken Essen-Mitte, Essen, Germany; Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, Sweden; Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany; Hokkaido Cancer Center, Sapporo, Japan; Breast Cancer Center, HELIOS Klinikum Berlin-Buch GmbH, Berlin, Germany; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Compass Oncology, US Oncology, Portland, OR; Texas Oncology, Austin, TX; Virginia Oncology Associates, Norfolk, VA; Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal; Centre Jean-Perrin, Clermont-Ferrand, France; Seoul National University, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Ramon y Cajal University Hospital, Madrid, Spain; Royal North Shore Hospital, Sydney, NSW, Australia; McGill University, Jewish General Hospital Segal Cancer Centre, Montréal, QC, Canada;; Merck & Co., Inc., Kenilworth, NJ; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX. |
|
| 8:30 am |
GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MMd, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Seoul National University Hospital, Seoul, Republic of Korea; Pantai Hospital, Kuala Lumpur, Malaysia; Arturo Lopez Perez Foundation, Santiago, Chile; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russian Federation; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; International Breast Cancer Center, Quiron Group, Barcelona, Spain;Aichi Cancer Center Hospital, Nagoya, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Oncomedica S.A., Monteria, Colombia; Ege University Medical Faculty, Izmir, Turkey; Peter McCallum Cancer Institute, Melbourne, Australia; Merck & Co., Inc., Kenilworth, NJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom. |
|
| 8:45 am |
GS1-03 Discussant
Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA |
|
| 9:00 am |
GS1-04 TBD |
|
| 9:15 am |
GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Dana-Farber Cancer Institute, Boston, MA; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA; National Cancer Center Hospital, Tokyo, Japan; NEXT Oncology, San Antonio, TX; Virginia Cancer Specialists, Fairfax, VA; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; Advanced Medical Development Center, Cancer Institute Hospital of JFCR, Tokyo, Japan; START Center for Cancer Care San Antonio, San Antonio, TX; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Daiichi Sankyo Inc, Basking Ridge, NJ; Daiichi Sankyo Co, Ltd, Tokyo, Japan. |
|
| 9:30 am |
GS1-06 A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, Ouyang Q, Wang J, Tong Z, Yan M, Li H, Zeng X, Shan C, Wang X, Yan X, Zhang J, Zhang Y, Wang J, Zhang L, Lin Y, Feng J, Chen Q, Huang J, Lu Y, Li H, Wu J, Cheng J, Hao Y, Geng C, Lu M, Li Y, Chen X, Song L, Wu X, Hu C, Wu X, Wang X, Pan Y, Cui Y, Guohua Yu, Sun S. Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Harbin Medical University Cancer Hospital, Harbin, China; Fudan University Shanghai Cancer Center, Shanghai, China; Liaoning Cancer Hospital & Institute, Liaoning, China; The First Hospital of Jilin University, Jilin, China; Hunan Cancer Hospital, Changsha, China; Linyi Cancer Hospital, Shandong, China; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; Henan Cancer Hospital, Zhengzhou, China; Beijing Cancer Hospital, Beijing, China; Chongqing University Cancer Hospital, Chongqing, China; Affiliated Hospital of Jining Medical University, Jining, China; Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou, China; West China Hospital, Sichuan University, Chengdu, China; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Jiangsu Cancer Hospital, Nanjing, China; Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Guangxi Medical University Cancer Hospital, Guangxi, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China; The First Affiliated Hospital of Hainan Medical University, Haikou, China; Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, China; The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, China; Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Fuzhou General Hospital, Fuzhou, China; Shandong Cancer Hospital, Jinan, China; Taizhou EOC Pharma Co., Ltd., Taizhou, China; Anhui Provincial Cancer Hospital, Hefei, China; Hubei Cancer Hospital, Wuhan, China; Zhejiang Cancer Hospital, Hangzhou, China; Anhui Provincial Hospital, Hefei, China; Zhongshan Hospital, Fudan University, Shanghai, China; Weifang People's Hospital, Weifang, China; Xuzhou Central Hospital, Xuzhou, China. |
|
| 9:45 am |
GS1-07 TBD |
|
| 10:00 am |
GS1-08 TBD |
|
| 10:15 am |
GS1-09 Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells
Tahaney WM, Qian J, Powell R, Moyer CL, Ma Y, Nguyen N, Hill J, Stephan C, Mazumdar A, Davies PJA, Brown PH. Baylor College of Medicine, Houston, TX; UT MD Anderson Cancer Center, Houston, TX; Texas A&M Institute for Biosciences and Technology, Houston, TX. |
|
| 10:30 am |
GS1-10 TBD |
|
| 10:00 am - 5:00 pm CT |
EXHIBITS |
|
| 10:45 am - 11:00 am CT |
BREAK |
|
| 11:00 am - 1:00 pm CT |
COVID Update |
|
| 11:00 am - 1:00 pm CT |
WORKSHOPS |
|
| |
Clinical Research: From Study Design to Scientific Presentation
Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA
How to select biomarkers rationally
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN
How to design an efficient clinical study
Valentina Nekljudova, PhD
German Breast Group
Neu Isenburg, German
How to include patient advocates in clinical research
Patty Spears
University of North Carolina at Chapel Hill
Chapel Hill, NC
How to present clinical research results effectively
George W. Sledge, Jr, MD
Stanford University School of Medicine
Stanford, CA
Basic Workshop: Basic Science for Breast Oncologists
Moderator: Alan Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT
Genome editing in human organoids as new models for discovery
Jennifer Rosenbluth, MD, PhD
University California San Francisco
San Francisco, CA
In silico experimentation from your living room: Tools to access and analyze existing datasets
Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH
Tricking T cells into action: Using patient-derived organoids to identify and expand tumor-specific T cells
Senthil K. Muthuswamy, PhD
Beth Israel Deaconess Medical Center
Boston, MA
Meeting the bar: How to tell when basic science discoveries are ready to translate
Bora Lim, MD
UT MD Anderson Cancer Center
Houston, TX
|
|
| 1:00 pm - 4:00 pm CT |
SPECIAL SESSION |
|
| |
Trust in Science and Healthcare
Co-Moderator: Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC
Co-Moderator: Maimah Karmo
Tigerlily Foundation
Stone Ridge, VA
Keynote #1
TBD
Panel 1: Equity in Research and Patient Care
TBD
Patient Advocates
Darcy Burbage, DNP, RN, AOCN
Newark, DE
Na'Diah Smith
Tigerlily Foundation
Keynote #2
Marcella Nunez-Smith, MD, MHS
Yale School of Medicine
New Haven, CT
Panel 2: Diversity in Clinical Trials – From Ideation to Implementation COVID Update
Erica Stringer-Reasor, MD
UAB Medicine
Birmingham, AL
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
Patient Advocates
Ashley Dedmon, MPH, CHES
Tigerlily Foundation
Ysabel Duron
The Latino Cancer Institute
|
|
| 4:00 pm - 5:00 pm CT |
Susan G. Komen® Brinker Awards for Scientific Distinction Lectures |
|
| |
Susan G. Komen® Brinker Awards for Scientific Distinction in Basic Science
TBD |
|
| |
Susan G. Komen® Brinker Awards for Scientific Distinction in Clinical Research
TBD |
|
| |
|
|
| 5:00 pm - 7:00 pm CT |
EDUCATIONAL SESSIONS
Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees
with a better understanding of the background leading up to talks they
will hear in the succeeding days, and some of the techniques that will
be used. These presentations should also provide researchers with ideas
and techniques to be considered for their own studies.
|
|
|
Triple Positive Breast Cancer
Moderator: Jenny C. Chang, MD, MB BChir
Houston Methodist Hospital
Houston, TX
The ideal partner to HER2 directed therapies
Sara A. Hurvitz, MD
UCLA
Los Angeles, CA
ER/HER2+ cross talk
Charles M. Perou, PhD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Escalating and de-escalation - titrating the right regimen in early stage HER2 positive
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany
Artificial Intelligence: Beyond the Soundbites
Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Everything you always wanted to know about AI but were afraid to ask
Regina Barzilay, PhD
MIT
Cambridge, MA
Artificial intelligence: Guiding the pathologists' eyes
Thomas J. Fuchs
Memorial Sloan Kettering Cancer Center
New York, NY
Artificial intelligence in radiology
TBD
Refining Heredity Risk
Moderator: Olufunmilayo (Funmi) Olopade, MD, FACP
University of Chicago
Chicago, IL
Reclassifying VUS: New techniques can solve the puzzle once and for all
Sean V. Tavtigian, PhD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, UT
Clinical management of moderate penetrance genes
Allison W. Kurian, MBBS, MD, MSc
Stanford University School of Medicine
Palo Alto, CA
Polygenic risk score: Should clinicians use it
Montserrat García-Closas, MD, DrPH
National Cancer Institute
Rockville, MD
Panel Discussion
Evidence Based Integrative Therapies - During and Beyond Treatment
Moderator: Dawn L. Hershman, MD, MS
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, NY
Acupuncture
Ting Bao, MD, DABMA, MS
Memorial Sloan Kettering Cancer Center
New York, NY
Hypnosis and mindfulness
David Spiegel, MD
Stanford University
Stanford, CA
Complementary treatments
Donald Abrams, MD
University of California, San Francisco
San Francisco, CA
What does diet and exercise change really do for you
Nicole Simone, MD
Thomas Jefferson University
Philadelphia, PA
Panel Discussion
|
|
|
|
|
| |
|
|
| 7:30 pm - 10:00 pm CT |
OPEN SATELLITE EVENTS
|
|
| |
|
|
|
|